Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Jun 02, 2011 8:14am
271 Views
Post# 18660835

RE: Anyone for take out?

RE: Anyone for take out?IMO it is not the right time for a takeout, assuming that the year and 2012 outlook proves to be real. If the share price gets north of $2.50 then management might consider it but until then realized fundamentals should drive the share price higher as we get passed Q2 and 2H reporting (again, assuming the growth in revenue and earnings is achieved with significant operating leverage). In the meantime it could be a choppy ride, but as we've seen before the stock could suddenly go significantly higher with little warning (recall up 50%+ in only 3 trading days earlier this year).

HEM is selling off lately along with RAVN and TRMB and I suspect the recent noise regarding potential GPS interference from the LightSquared increased spectrum request is the reason (and some questions about planting progress due to flooding). FCC would never allow GPS interference to occur, so likely to see a formal study that either proves no interference, or if interference then a rejection of the LightSquared request. In the meantime though it is negative noise on the GPS industry but those in the know think there is no chance of any real threat happening. Net, net a great time to pick up some cheap HEM shares.



Bullboard Posts